ResultsIQ

ResultsIQ › Latest results › Anuh Pharma Limited

Anuh Pharma Limited Q1 FY27 results deck summary

NSE: ANUHPHR · BSE: 506260

Results deck of 19 Aug 2026, summarised by AI from the filing.

Anuh Pharma Q1 FY27 operating revenue ₹193.81 cr (+3.93% YoY) with PAT ₹11.42 cr (+37.63% YoY) and EBITDA margin 9.99%.

Key takeaways

  1. Q1 FY27 revenue Operating revenue ₹193.81 cr (Q1 FY26: ₹186.48 cr, +3.93% YoY), with PAT ₹11.42 cr (+37.63% YoY).
  2. Margin expansion EBITDA margin 9.99% in Q1 FY27 vs 7.34% in Q1 FY26, on richer product mix and cost control.
  3. Regulated markets With USFDA and EU GMP clearances secured, the regulated-market pipeline is the primary engine of growth.

Original filing on BSE

Anuh Pharma Limited Q1 FY27 results

As filed: Revenue ₹194 cr (+4% year on year), EBITDA ₹16.3 cr (+48% year on year), PAT ₹11.4 cr (+43% year on year), EBITDA margin 8.4% (+249 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹202 cr (+2% year on year), EBITDA ₹19.9 cr (+5% year on year), PAT ₹11.7 cr (−3% year on year), EBITDA margin 9.8% (+24 bps). Score 35 of 100, Below trend. EBITDA margin rose 24 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: −4.4% in 30 days (Nifty 500: +2.5%).
  • Q3 FY26: Revenue ₹197 cr (+23% year on year), EBITDA ₹16.8 cr (+20% year on year), PAT ₹13.5 cr (+35% year on year), EBITDA margin 8.5% (−23 bps). Score 68 of 100, Above trend. EBITDA margin fell 23 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.1% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹186 cr, EBITDA ₹12.0 cr, PAT ₹8.0 cr, EBITDA margin 6.5%. Not scored. No result for the same quarter last year. Share price after the results: −4.3% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹186 cr, EBITDA ₹11.0 cr, PAT ₹8.0 cr, EBITDA margin 5.9%. Not scored. No result for the same quarter last year. Share price after the results: −7.0% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹198 cr, EBITDA ₹19.0 cr, PAT ₹12.0 cr, EBITDA margin 9.6%. Not scored. No result for the same quarter last year. Share price after the results: −0.4% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹160 cr, EBITDA ₹14.0 cr, PAT ₹10.0 cr, EBITDA margin 8.8%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Anuh Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.